Navigation Links
King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology
Date:10/31/2007

the License, Development and Commercialization Agreement

The Agreement provides King with an exclusive license in the Territory for ACUROX(TM) Tablets (formerly OxyADF) and another undisclosed opioid product utilizing Acura's Aversion(R) Technology. In addition, the Agreement provides King with an option to license in the Territory all future opioid analgesic products developed utilizing Acura's Aversion(R) Technology.

Under the terms of the Agreement, King will make an upfront cash payment to Acura of $30 million. Depending on the achievement of certain development and regulatory milestones, King could also make additional cash payments to Acura of up to $28 million relating to ACUROX(TM) Tablets and similar amounts with respect to each subsequent Aversion(R) Technology product developed under the Agreement. King will reimburse Acura for all research and development expenses incurred beginning from September 19, 2007 for ACUROX(TM) Tablets and all research and development expenses related to future products after King's exercise of its option to an exclusive license for each future product. King will record net sales of all products and pay Acura a royalty ranging from 5% to 25% based on the level of combined annual net sales for all products subject to the Agreement. King will also make a one-time cash payment to Acura of $50 million in the first year in which the combined annual net sales of all products exceed $750 million.

King and Acura will form a joint steering committee to coordinate development and commercialization strategies. With King's oversight, Acura will conduct all ACUROX(TM) Tablet development activities through approval of a New Drug Application ("NDA") and thereafter King will commercialize ACUROX(TM) in the U.S. With respect to all other products subject to the Agreement, King will be responsible for development and regulatory activities following either acceptance of an Investigational New Drug Application by the U.S. Food a
'/>"/>

SOURCE King Pharmaceuticals, Inc.; Acura Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... The news is full of companies getting ... documentation or appropriate training: an automobile manufacturer, a store ... company in Texas and the list goes on. The ... due to improper training and documentation (Osha.gov). eLeaP ... the new Supervisor feature which provides a powerful tool ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Danish scientists ... line” biomarkers that have the potential to help in ... to read the full story that has just ... University in Aalborg, Denmark say new biomarkers found in ... outlook for patients with malignant mesothelioma . ...
(Date:5/27/2015)... The Society for Women's Health Research ... research on sex differences in health and disease, today ... advocates, organizations, and celebrities in bringing awareness to the ... campaign features a short film that shares the stories ... as a result of their abuse, as well as ...
(Date:5/27/2015)... May 27, 2015 National ... partner, award winning web development and interactive ... announce the launch of its newly redesigned, ... , National Healthcare Providers, is a physician ... in the areas of Radiology, Anesthesiology, Emergency ...
(Date:5/27/2015)... silver spring, MD (PRWEB) May 27, 2015 ... Company in USA, helped its client to launch an ... Payment app allows merchants to accept credit, debit and ... be downloaded from Google Play at: https://play.google.com/store/apps/details?id=com.simpalm.paymentgateway . ... Jan 2013 and has been recently updated by SIMpalm. ...
Breaking Medicine News(10 mins):Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 2Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 3Health News:New Report Highlights Current and Emerging Biomarkers for Mesothelioma, According to Surviving Mesothelioma 2Health News:The Society for Women’s Health Research Announces “Beyond the Bruises” Campaign Highlighting the Effects of Domestic Violence on Chronic Disease 2Health News:The Society for Women’s Health Research Announces “Beyond the Bruises” Campaign Highlighting the Effects of Domestic Violence on Chronic Disease 3Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 2Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 3Health News:Forte Payment System Launches Android Version of Payment App 2
... CARLSBAD, Calif., Oct. 2 Isis,Pharmaceuticals, Inc. (Nasdaq: ... received,clearance under the Hart-Scott-Rodino Antitrust Improvements Act for ... company, which,was announced on September 13, 2007. ... to Ortho-McNeil,worldwide development and commercialization rights to two ...
... for a loved one with dementia, TUCSON, Ariz., ... a new book that aims to ease the challenges ... and,Families are Still Asking WHY?, author Jim Greenwood, whose ... and useful,advice on how to best care for a ...
... Recruitment Efforts for Pulmonary Study, SOLANA ... Solutions, LLC, a firm specializing in patient ... its team of Regional Recruitment,Specialists(TM) in support ... of,Chronic Obstructive Pulmonary Disease (COPD) for a ...
... for Massachusetts Firms, WASHINGTON, Oct. 1 ... bill with provisions secured by,Senator John Kerry (D-Mass.) ... through 2010 and to increase the transition and,commercialization ... will ensure that the thousands of firms that ...
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) announced ... (FDA) has approved the SymlinPen(TM) 120 and ... acetate) injection. These new pre-filled pen-injector devices,feature ... control. "SymlinPen 120 and SymlinPen 60 ...
... any period of time after leaving the foster care ... than those with stable housing situations, according to a ... & Adolescent Medicine, one of the JAMA/Archives journals. Youth ... after leaving the foster care system appear to have ...
Cached Medicine News:Health News:Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc. 2Health News:Alzheimer's Caregivers Get Sage Advice 2Health News:RESolutions Rapid Enrollment Solutions, LLC Mobilizes Team of Regional Recruitment Specialists(TM) 2Health News:Kerry Extends, Improves Small Business Innovation Program 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 3Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 4Health News:Poor health care access common among youth leaving foster system 2Health News:Poor health care access common among youth leaving foster system 3
(Date:5/27/2015)... 2015 Una presentazione speciale durante la settimana ... esperti di MERG valutare i successi ottenuti ... di svariate popolazioni di pazienti affetti dalla patologia. ... Ronnie Fass , MD della Case Western Reserve ... clinici relativi alla terapia Stretta. Un panel di esperti ...
(Date:5/27/2015)... Biosensors International Group, Ltd. ("Biosensors " or the "Company", ... manufacturer and marketer of innovative medical devices, today announced ... and fiscal full year ended 31 March 2015 ("FY15"). ... , Q4 FY15: , Total revenue of US$75.9 ... Year 2014 ("Q4 FY14") due to licensing revenue reduction ...
(Date:5/27/2015)... , May 27, 2015  PDL BioPharma, Inc. (PDL) ... P. McLaughlin , the company,s president and chief executive ... Conference next week in New York City.  The presentation, ... 3, 2015 at 11:30 a.m. EDT. To ... presentation, go to the Company,s website at http://www.pdl.com ...
Breaking Medicine Technology:Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 2Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 3Alla Settimana delle malattie digestive, la terapia Stretta è stata presentata come un trattamento versatile ed efficace per svariate popolazioni di pazienti affetti dalla patologia MERG 4Biosensors Reports Financial Results for Fiscal Year 2015 2Biosensors Reports Financial Results for Fiscal Year 2015 3Biosensors Reports Financial Results for Fiscal Year 2015 4Biosensors Reports Financial Results for Fiscal Year 2015 5Biosensors Reports Financial Results for Fiscal Year 2015 6Biosensors Reports Financial Results for Fiscal Year 2015 7PDL BioPharma to Present at Jefferies 2015 Global Healthcare Conference 2
... Encouraging 12-Month Outcomes from, Single- Center Study Involving ... 14 OrbusNeich today announced that an,interim analysis ... show good safety and efficacy in the real-world ... Presented by Professor Robbert de Winter, M.D., Ph.D., ...
... study Study needed ... Oct. 13 Advanced Circulatory Systems, Inc.,( http://www.advancedcirculatory.com ) ... in funding from the National Institutes of,Health (NIH) to ... on,those who experience cardiac arrest outside a hospital. Whatcom ...
Cached Medicine Technology:Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 3Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2
... Sysmex UF-50 is designed to bring efficiency ... It combines the superior technology of ... sample analysis. Continuous sampling or batch ... autosamplers, streamlining sample processing in high volume ...
... The iQ200 System incorporates the ... and the AUTION MAX™ AX-4280 Automated ... a fully integrated chemical and microscopic ... (APR™), a well trained neural network, ...
... The Sysmex UF-100 is designed to bring ... analysis. It combines the superior technology ... urine sample analysis. Continuous sampling or ... rack-based autosamplers, streamlining sample processing in high ...
... easy to use Ambulatory Urodynamic recorder which ... practising urologists as an invaluable aid in ... The system offers the possibility to measure ... natural bladder filling, extented over a longer ...
Medicine Products: